PMID- 21493313
OWN - NLM
STAT- MEDLINE
DCOM- 20110829
LR  - 20111024
IS  - 1097-6817 (Electronic)
IS  - 0194-5998 (Linking)
VI  - 145
IP  - 1
DP  - 2011 Jul
TI  - Human papillomavirus in metastatic lymph nodes from unknown primary head and neck 
      squamous cell carcinoma.
PG  - 51-7
LID - 10.1177/0194599811400385 [doi]
AB  - OBJECTIVE: Determine human papillomavirus (HPV) incidence in unknown primary 
      squamous cell carcinomas (SCCa) of the head and neck and assess if HPV status 
      influenced survival. STUDY DESIGN: Historical cohort study. SETTING: Tertiary 
      care center. SUBJECTS: Patients with unknown primary SCCa despite a complete 
      workup who underwent neck dissection or excisional biopsy and postoperative 
      comprehensive +/- chemoradiotherapy between 2002 and 2009. METHODS: HPV 
      fluorescence in situ hybridization (FISH) and p16(INK4a) immunohistochemistry 
      (p16 IHC) were performed. Results were compared with survival, age, race, gender, 
      tobacco use, alcohol use, and nodal stage. RESULTS: Twenty-five patients met the 
      inclusion criteria, of whom 88% were >10 pack year tobacco users. Twenty-eight 
      percent were HPV-positive defined by both p16+ and FISH+. Five-year overall 
      survival was 66.7% in HPV-positive and 48.5% in HPV-negative patients (P = .35). 
      Similarly, 5-year disease-free survival rates were 66.7% in HPV-positive and 
      48.5% in HPV-negative patients (P = .54). All 3 HPV-positive nonsmokers were 
      survivors, but this was not significant because of the small sample size (P > 
      .05). No other characteristics were associated with survival (P > .05). 
      CONCLUSION: Twenty-eight percent of metastatic lymph nodes from occult primary 
      tumors were HPV positive. There was no survival difference associated with HPV 
      status. Most of the HPV-positive patients in this study were tobacco users who 
      had similar survival to HPV-negative patients, so caution should be used in 
      interpreting HPV status in these patients.
FAU - Compton, Andrew M
AU  - Compton AM
AD  - Department of Otolaryngology-Head and Neck Surgery, Louisiana State University 
      Health Sciences Center, Shreveport, Louisiana, USA.
FAU - Moore-Medlin, Tara
AU  - Moore-Medlin T
FAU - Herman-Ferdinandez, Lilantha
AU  - Herman-Ferdinandez L
FAU - Clark, Cheryl
AU  - Clark C
FAU - Caldito, Gloria C
AU  - Caldito GC
FAU - Wang, Xiaohong Iris
AU  - Wang XI
FAU - Thomas, Jaiyeola
AU  - Thomas J
FAU - Abreo, Fleurette W
AU  - Abreo FW
FAU - Nathan, Cherie-Ann O
AU  - Nathan CO
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Otolaryngol Head Neck Surg
JT  - Otolaryngology--head and neck surgery : official journal of American Academy of 
      Otolaryngology-Head and Neck Surgery
JID - 8508176
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p16)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Biopsy
MH  - Carcinoma, Squamous Cell/mortality/*pathology/*secondary/therapy/*virology
MH  - Combined Modality Therapy
MH  - Cyclin-Dependent Kinase Inhibitor p16/analysis
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - *Human papillomavirus 16
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - In Situ Hybridization, Fluorescence
MH  - Kaplan-Meier Estimate
MH  - Lymph Nodes
MH  - Lymphatic Metastasis/*pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Neoplasms, Unknown Primary/mortality/*pathology/therapy/*virology
MH  - Otorhinolaryngologic Neoplasms/mortality/*pathology/*secondary/therapy/*virology
MH  - Papillomavirus Infections/*pathology/surgery/*virology
MH  - Smoking/adverse effects/pathology
EDAT- 2011/04/16 06:00
MHDA- 2011/08/30 06:00
CRDT- 2011/04/16 06:00
PHST- 2011/04/16 06:00 [entrez]
PHST- 2011/04/16 06:00 [pubmed]
PHST- 2011/08/30 06:00 [medline]
AID - 0194599811400385 [pii]
AID - 10.1177/0194599811400385 [doi]
PST - ppublish
SO  - Otolaryngol Head Neck Surg. 2011 Jul;145(1):51-7. doi: 10.1177/0194599811400385.